Key facts
- Leucid Bio’s last known valuation is $25.0M (Feb 2025).
- It has raised $30.8M; the latest was Later Stage VC ($9.3M) in Feb 2025.
- Notable investors include British Business Bank, Sofinnova Partners, 2invest, 4basebio, Epidarex Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Leucid Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Leucid Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leucid Bio
Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatment options. The company specializes in the development of chimeric antigen receptor (CAR) T-cell therapies that produce a durable response than previous CAR T generations, enabling healthcare professionals to improve treatment outcomes and save the lives of patients with refractory cancers.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2014
- Employees
- 24
- Website
- leucid.com/
- Ownership
- Privately Held (backing)
Leucid Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leucid Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leucid Bio in its N-PORT filings yet. We sweep new filings monthly.